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Significance of this study
What is already known about this subject?
 ► Patients with type 1 diabetes are more susceptible 
to hypertension and increased cardiovascular risk.
 ► Increased salt sensitivity may underlie this phenom-
enon; however, evidence is scarce and conflicting.
What are the new findings?
 ► Young, normoalbuminuric and normotensive pa-
tients with type 1 diabetes are more salt- sensitive 
compared with matched healthy individuals.
 ► The salt- sensitive blood pressure (BP) increase in 
patients with type 1 diabetes was accompanied by 
significant increases in plasma volume, cardiac out-
put, heart rate, and N- terminal pro- B- type natriuretic 
peptide.
How might these results change the focus of 
research or clinical practice?
 ► These findings underline the benefit of dietary salt 
restriction in patients with type 1 diabetes to control 
BP.
 ► Future research is required to assess potential 
mechanisms underlying the observed responses to 
salt in patients with type 1 diabetes.
AbStrAct
Introduction Patients with type 1 diabetes are susceptible 
to hypertension, possibly resulting from increased salt 
sensitivity and accompanied changes in body fluid 
composition. We examined the effect of a high- salt diet 
(HSD) in type 1 diabetes on hemodynamics, including 
blood pressure (BP) and body fluid composition.
Research design and methods We studied eight male 
patients with type 1 diabetes and 12 matched healthy 
controls with normal BP, body mass index, and renal 
function. All subjects adhered to a low- salt diet and HSD 
for eight days in randomized order. On day 8 of each diet, 
extracellular fluid volume (ECFV) and plasma volume 
were calculated with the use of iohexol and 125I- albumin 
distribution. Hemodynamic measurements included BP, 
cardiac output (CO), and systemic vascular resistance.
Results After HSD, patients with type 1 diabetes showed 
a BP increase (mean arterial pressure: 85 (5) mm Hg vs 80 
(3) mm Hg; p<0.05), while BP in controls did not rise (78 
(5) mm Hg vs 78 (5) mm Hg). Plasma volume increased 
after HSD in patients with type 1 diabetes (p<0.05) and not 
in controls (p=0.23). There was no significant difference 
in ECFV between diets, while HSD significantly increased 
CO, heart rate (HR) and N- terminal pro- B- type natriuretic 
peptide (NT- proBNP) in type 1 diabetes but not in controls. 
There were no significant differences in systemic vascular 
resistance, although there was a trend towards an HSD- 
induced decrease in controls (p=0.09).
Conclusions In the present study, patients with type 1 
diabetes show a salt- sensitive BP rise to HSD, which is 
accompanied by significant increases in plasma volume, 
CO, HR, and NT- proBNP. Underlying mechanisms for these 
responses need further research in order to unravel the 
increased susceptibility to hypertension and cardiovascular 
disease in diabetes.
Trial registration numbers NTR4095 and NTR4788.
InTRoduCTIon
Type 1 diabetes is associated with an increased 
risk of hypertension and hypertension- 
mediated complications.1 2 In a large cohort 
study, hypertension prevalence in patients 
with type 1 diabetes was estimated to be 
43% compared with 15% in healthy controls 
matched for age and sex.3 The increased 
susceptibility to hypertension may result 
from increased sensitivity to high salt (NaCl) 
intake. Although hypertensive patients with 
type 1 diabetes do not appear to be more 
salt- sensitive than patients with hypertension 
in general,4 there is evidence that normoten-
sive patients with type 1 diabetes are more 
salt- sensitive compared with control subjects 
matched for age, gender, and body mass 
index (43% vs 17% that were classified as salt- 
sensitive, which was defined as a ≥3 mm Hg 
increase in mean arterial pressure (MAP)).5 
However, there are also studies that suggest 
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that salt sensitivity is more or only apparent in case of 
microalbuminuria.6–8
Increased sodium retention by the kidney is thought to 
be the principal determinant of the relation between high- 
salt intake and hypertension, by leading to an increase 
in extracellular fluid volume (ECFV) and stroke volume, 
resulting in a subsequent rise in blood pressure (BP).9 
Patients with type 1 diabetes are suggested to have alter-
ations in body fluid composition (including increased 
venous blood volume10 and increased ECFV11 12) and 
might respond differently to high- salt consumption in 
terms of ECFV or plasma volume compared with healthy 
individuals. However, studies that support this assump-
tion have never been conducted. Moreover, importantly, 
there is an increasing body of literature that questions 
the validity of the classical volume theory.13–16
Therefore, a careful assessment of responses in patients 
with type 1 diabetes to dietary high salt is warranted.
The primary aim of the present study was to investi-
gate the effect of salt on BP and body fluid composition 
(ie, ECFV and plasma volume) in patients with type 1 
diabetes. Additionally, the effect of salt on cardiac output 
(CO) and systemic vascular resistance was assessed.
ReseaRCH desIgn and meTHods
Participants
We carried out two identical randomized cross- over 
intervention studies in patients with type 1 diabetes 
and healthy controls, respectively. Male, non- smoking 
individuals between 18 and 40 years old who were able 
to provide written informed consent were included. 
Patients with type 1 diabetes had to have a normal and 
stable renal function and stable hemoglobin A1c levels 
between 6% and 10% (42–86 mmol/mol) during the six 
months preceding the study. Use of renin–angiotensin 
system blocking agents was allowed for patients with type 
1 diabetes, but these were discontinued prior to the study 
visits for five times the elimination half- life. Insulin doses 
were kept stable throughout the whole study period. We 
excluded overweight subjects (body mass index>30 kg/
m2), subjects with a BP of 140/90 mm Hg or higher, 
and subjects with decreased kidney function (estimated 
glomerular filtration rate<60 mL/min). The trials were 
conducted in accordance to the original protocols ( www. 
trialregister. nl) and the reporting adheres to the Consoli-
dated Standards of Reporting Trials guidelines.17
study design and measurements
The primary endpoint of this study was ECFV. Secondary 
endpoints were plasma volume and hemodynamics (ie, 
systemic vascular resistance and CO, consisting of stroke 
volume and heart rate (HR)). Our null hypothesis was 
that there would be no difference in BP and body fluid 
composition between diets. Salt loading was pursued 
by means of a dietary protocol, which is considered to 
be the current reference method for testing the effects 
of salt.18 All subjects adhered to an 8- day low- salt diet 
(LSD) (<3 g NaCl/day) and high- salt diet (HSD) (>12 
g NaCl/day) in randomized order and a time period of 
1–2 weeks with a normal diet in- between. Diet order was 
determined by block randomization via sealed envelopes 
by the study investigators, and diets were not masked for 
the study subjects or investigators during follow- up. Diets 
were pursued with the help of a dietary list, which advised 
to resemble the normal diet of the individual as much 
as possible, for example, by adding extra salt instead of 
changing the whole dietary pattern. We checked dietary 
compliance by collecting 24- hour urine samples on day 
3, 6 and 8. The measurements on day 8 were used for 
analysis and are depicted in the tables. Also, on day 8 
(the last day of the diet), blood sampling and hemody-
namic measurements were performed. Plasma–renin 
activity (PRA) was measured by enzyme- kinetic assay as 
described before.19 Aldosterone was measured by radio-
immunoassay (Demeditec Diagnostics, Kiel, Germany).20 
Brachial BP was measured in supine position with a semi-
automatic device (Omron 705 IT, OMRON Healthcare, 
The Netherlands) after at least 10 min of supine rest in a 
quiet and temperature- controlled room. We performed 
five sequential measurements and used the mean of last 
two readings for analysis. MAP was calculated by the sum 
of two- thirds∙(diastolic BP) and one- third∙(systolic BP). 
CO and HR were measured after at least 15 min of supine 
rest with the Nexfin device (Edward Lifesciences BMEYE 
B.V., Amsterdam, the Netherlands). This device deter-
mines stroke volume using the pulse contour method 
(Nexfin CO- trek) and divides it by the interbeat interval 
to calculate CO.21 The parameters are determined from 
the average of a 30 s stable recording period. Systemic 
vascular resistance (SVR) was calculated by dividing 
the MAP by CO. Solute- mediated water clearance and 
solute- free water clearance were calculated from the 
urinary osmolality, total urine volume, and plasma osmo-
lality, and electrolyte- free clearance was calculated from 
urinary sodium and potassium concentrations, total 
urine volume, and plasma osmolality.22 These clearances 
were used to assess to what extent the diuresis is driven by 
urinary solutes or electrolytes. Subjects were instructed 
to refrain from alcohol intake and heavy physical exer-
cise 24 hours prior to the study visit and to avoid caffeine 
intake 12 hours in advance.
eCFV and plasma volume
At the study visit, two intravenous catheters were placed 
in the left and right antecubital veins. Iohexol (Omni-
paque 647 mg iohexol/mL), a non- ionic radiopaque 
contrast agent that is distributed throughout the whole 
extracellular space, was used to measure ECFV according 
to the method by Zdolsek et al.23 We administered 10 mL 
iohexol at day 8 of both diets through a venous catheter. 
Because of relatively rapid elimination by the kidneys, 
a reasonably steady state is never reached, and contin-
uous elimination of iohexol must be considered in the 
calculations. Therefore, blood was drawn at regular time 
intervals after infusion of iohexol (t=0, 5, 10, 15, 30, 60, 
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90, 120, 150, 180 and 240 min after infusion). For ECFV 
calculation, a two- compartment kinetic model with an 
expected distribution phase of approximately 20 min was 
fitted to the data.23 The obtained values were multiplied 
by 0.934 to account for the water content of plasma.24
Plasma volume was measured by labeled human serum 
albumin (125I- albumin). A 125I- albumin solution of 100 
kBq in 5 mL saline was administered intravenously. Blood 
samples were drawn at the contralateral arm at regular 
time intervals after infusion (t=0, 5, 10, 15, 20, 30, 45 and 
60 min after infusion). One urine sample was obtained at 
t=60 min. Plasma radioactivity was measured in the blood 
and urine samples using a scintillation detector (Wizard2 
2480 Automatic Gamma Counter (PerkinElmer, USA), 
measuring in duplicate with a coefficient of variation 
of <3%. The routine quality control tasks of the gamma 
counter were performed according the standard Good 
Laboratory Practice (GLP) features of PerkinElmer, 
including detector energy resolution, background, abso-
lute and relative detector efficiency, detector stability 
probability and calibration. Plasma volume was deter-
mined by calculating the y- intercept of the disappearance 
curve of 125I- albumin, corrected for the injected dose of 
tracer, according to the method described by van Kreel 
et al.25
ECFV and plasma volume calculations were done with 
PKSolver, a free Microsoft Excel add- in validated for phar-
macokinetic (PK) and pharmacodynamic data analysis.26
statistical analysis
Data were expressed as mean with SE or SD for parametric 
and median with IQR for non- parametric variables. 
Differences between LSD and HSD were assessed using 
paired t- tests for parametric distributions and Wilcoxon 
rank- sum test for non- parametric distributions. To assess 
differences between patients with type 1 diabetes and 
healthy controls, unpaired t- tests and Mann- Whitney 
tests were used. The presence of time order and carry- 
over effects was tested by comparing the means between 
the two diet orders.27 To test for associations, Pearson’s 
or Spearman’s correlation coefficient for parametric or 
non- parametric data were used. All statistical analyses 
were performed using IBM SPSS Statistics V.22.0. A p 
value of <0.05 was considered significant.
sample size calculation
We used anticipated changes in BP and body weight for 
the sample size calculation, with the latter serving as a 
proxy for ECFV, since there were no data on measured 
ECFV after HSD.
As for the patients with type 1 diabetes, we calculated 
that a sample size of five subjects would have 80% power 
to detect a difference in BP of 4 mm Hg between a LSD 
and HSD (based on a two- sided t- test, alpha error of 
5%) using data from the study of Strojek et al.5 In a pilot 
experiment, we showed that, after changing from an LSD 
to an HSD, the difference in body weight was 1.7 (SD 1.0) 
kg between subjects on an LSD and an HSD, according 
to which we calculated that at least six subjects would 
be needed for each group (based on a two- sided t- test; 
power of 80%, alpha error of 5%). Taking into account a 
possible drop- out of subjects after inclusion, we decided 
to include at least eight patients with type 1 diabetes.
As for the healthy subjects, at least six subjects were 
needed for each group to demonstrate a 1.7 (SD 1.0) 
kg body weight difference between subjects on LSD 
and HSD (based on a two- sided t test; power of 80%, 
alpha error of 5%). We demonstrated a 5 mm Hg (SD 
5) systolic BP difference between healthy subjects in our 
pilot on LSD and HSD, indicating that at least 10 subjects 
were needed (two- sided t- test; power of 80%, alpha 
error of 5%). Taking into account possible drop- out of 
subjects after inclusion, we decided to include at least 12 
healthy subjects. Of this trial, one article was published 
previously.28
ResulTs
Population and dietary intervention
We screened nine patients with type 1 diabetes (between 
March 2015 and November 2015) and 19 healthy controls 
(between March 2013 and Augustus 2014). Of the patients 
with type 1 diabetes, one patient had to be excluded 
due to a body mass index of >30 kg/m2. Of the healthy 
controls, four subjects withdrew their consent after 
inclusion before randomization and three subjects were 
excluded before randomization (one due to high BP and 
two others due to difficulties with blood drawing). There-
fore, we included eight patients with type 1 diabetes and 
12 healthy controls with mean ages of 28 (SD 6) and 22 
(SD 4) years, respectively, with a normal and similar BP, 
body mass index, and renal function. Detailed baseline 
characteristics (determined at a screening visit before 
commencement of the diets) are depicted in online 
supplementary table 1. There was no loss to follow- up, 
and all subjects were included in our analyses. All subjects 
adequately followed dietary instructions, as assessed by 
24- hour urine sodium excretion. Mean (SD) 24- hours 
urine sodium excretion of patients with type 1 diabetes 
and healthy controls was 23 (SD 13) mmol and 19 (SD 
10) mmol after LSD, and was 353 (SD 73) mmol and 341 
(SD 104) mmol after HSD, respectively (table 1). One 
of the eight patients with type 1 diabetes used a renin–
angiotensin system blocking agent (lisinopril), which was 
temporarily discontinued during the study (as indicated 
in the Research design and methods section). No other 
medication (except insulin for the patients with type 1 
diabetes) was used by the study subjects.
Patients with type 1 diabetes demonstrate a salt-sensitive BP 
increase
In patients with type 1 diabetes, MAP was significantly 
higher after HSD than after LSD (mean 84.6 (SD 5.1) 
mm Hg vs 80.3 (SD 3.5) mm Hg, p=0.03; figure 1A and 
table 1), while MAP was similar after HSD and LSD in 
healthy controls (77.8 (SD 4.8) mm Hg vs 78.0 (SD 4.8) 
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Table 1 Data are depicted as mean (SD), unless marked with * (median and 95% CI of the median)
Patients with type 1 diabetes (n=8) Healthy controls (n=12)
LSD HSD P value LSD HSD P value
Weight (kg) 75.6 (8.8) 78.2 (9.6) <0.001 74.0 (6.6) 76.5 (6.7) <0.001
Extracellular fluid volume (L) 14.6 (2.2) 16.1 (2.8) 0.32 15.1 (3.6) 17.1 (2.6) 0.09
Plasma volume (L) 3.2 (0.5) 3.5 (0.6) <0.05 3.4 (0.6) 3.6 (0.6) 0.23
Hemodynamics
  Systolic BP (mm Hg) 120.0 (4.5) 126.4 (7.4) <0.05 117.3 (7.8) 118.8 (5.5) 0.33
  Diastolic BP (mm Hg) 60.4 (5.2) 63.6 (5.0) <0.05 58.3 (5.4) 57.4 (5.4) 0.28
  MAP (mm Hg) 80.3 (3.5) 84.6 (5.1) <0.05 78.0 (4.8) 77.8 (4.8) 0.85
  Cardiac output (L/min) 6.6 (0.8) 7.2 (0.7) <0.05 6.5 (1.0) 7.0 (1.3) 0.10
  Heart rate (beats/min) 57.5 (10.1) 63.1 (10.7) <0.01 54.7 (8.0) 58.9 (11.2) 0.06
  Stroke volume (mL) 116.2 (14.3) 116.7 (18.9) 0.87 118.9 (12.0) 120.5 (8.4) 0.67
  Systemic vascular 
resistance (dyn·s·cm−5)
991.3 (127.6) 940.2 (94.6) 0.21 983.4 (174.0) 907.3 (154.6) 0.09
Plasma
  PRA (pmol AngI/mL/hour)* 0.48 (0.24–0.70) 0.08 (0.04–0.13) <0.01 0.36 (0.17–0.63) 0.04 (0.00–0.07) <0.001
  Aldosterone (pg/mL)* 142.6 (130.7–272.9) 34.4 (20.8–52.1) <0.001 204.2 (49.3–455.3) 28.0 (15.2–64.2) <0.001
  Aldosterone:PRA ratio*
  (pg/mL/pmol AngI/mL/
hour)
699.5 (216.1–959.8) 667.7 (415.8–5067) 0.31 410.4 (361.6–512.9) 443.3 (263.0–566.7) 0.68
  NT- proBNP (ng/L) 10.3 (6.2) 51.8 (45.4) <0.05 12.7 (13.4) 20.8 (15.7) 0.15
  Sodium (mmol/L) 137.3 (2.4) 139.8 (2.1) <0.05 137.5 (1.6) 140.3 (1.8) <0.01
  Potassium (mmol/L) 4.3 (0.3) 4.2 (0.3) 0.41 3.9 (0.3) 3.9 (0.2) 0.76
  Chloride (mmol/L) 98.0 (2.3) 101.9 (1.6) <0.05 99.6 (1.5) 103.3 (2.0) <0.001
  Bicarbonate (mmol/L) 25.2 (2.5) 25.6 (2.0) 0.77 25.5 (2.0) 25.4 (1.6) 0.88
  Creatinine (μmol/L) 75.1 (10.1) 70.6 (9.9) 0.12 83.9 (10.0) 77.0 (9.2) <0.001
  eGFR (CKD- EPI) 116.9 (10.6) 120.9 (10.2) 0.08 111.7 (14.1) 119.9 (11.7) <0.01
  Osmolality (mOsm/kg) 290.3 (2.1) 297.6 (6.1) <0.01 284.9 (3.1) 289.6 (3.8) <0.01
  Glucose (mmol/L) 10.7 (4.0) 11.0 (2.9) 0.88 4.9 (0.3) 5.0 (0.4) 0.70
24- hour urine
  Volume (mL/24 hours) 2246 (1044) 2809 (788) <0.05 1702 (551) 1909 (544) 0.24
  Osmolality (mOsm/kg) 447.1 (209.5) 650.3 (222.1) <0.05 430.9 (164.4) 743.7 (164.8) <0.001
  Creatinine (mmol/24 hours) 16.5 (2.6) 17.9 (3.4) <0.05 15.8 (2.4) 17.3 (2.5) <0.05
  FeNa (%) 0.1 (0.03) 1.0 (0.2) <0.001 0.1 (0.03) 1.1 (0.5) <0.001
  Sodium (mmol/24 hours) 23.3 (13.0) 352.7 (72.6) <0.001 19.1 (9.5) 340.8 (104) <0.001
  Potassium (mmol/24 hours) 113.8 (36.3) 105.8 (38.9) 0.51 90.4 (25.4) 89.5 (19.7) 0.93
  Solute- free water 
clearance (L/day)
−0.8 (1.6) −3.0 (1.8) <0.01 −0.7 (0.7) −2.8 (0.5) <0.001
  Solute- mediated water 
clearance (L/day)
3.1 (0.8) 5.8 (1.8) <0.001 2.4 (0.5) 4.7 (0.6) <0.001
  Electrolyte- free water 
clearance (L/day)
1.2 (0.9) −0.5 (1.0) <0.001 0.9 (0.6) −1.2 (0.3) <0.001
Data are tested using paired t- test (LSD vs HSD) or Wilcoxon test if marked with *.
BP, blood pressure; CKD- EPI, Chronic Kidney Disease Epidemiology Collaboration; eGFR, estimated glomerular filtration rate; FeNa, fractional excretion of sodium; HSD, high- salt 
diet; LSD, low- salt diet; MAP, mean arterial pressure; NT- proBNP, N- terminal pro- B- type natriuretic peptide; PRA, plasma–renin activity.
mm Hg, p=0.85; figure 1A and table 1). Likewise, systolic 
BP and diastolic BP were higher after HSD in patients 
with type 1 diabetes but not in healthy controls (table 1). 
The BP rise in patients with type 1 diabetes did not coin-
cide with a higher difference in 24- hour urinary sodium 
excretion between LSD and HSD (figure 1A), and BP 
changes were not correlated to plasma sodium or urinary 
sodium excretion. Furthermore, the BP rise in patients 
with type 1 diabetes coincided with increased diuresis 
after HSD (figure 1B and table 1). Solute- free water clear-
ance and electrolyte- free water clearance decreased after 
HSD, whereas solute- mediated water clearance increased, 
all to a similar extent in both groups (table 1).
Responses to Hsd in patients with type 1 diabetes and 
controls
In patients with type 1 diabetes, HSD induced signifi-
cant increases in body weight, BP, CO, HR, N- terminal 
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Figure 1 Differences in UNa versus differences in map 
and UVol between LSD and HSD. (A) Similar increases in 
UNa in the patients with DM1 and the HCs coincided with 
distinct MAP responses. (B) Similar increases in UNa in the 
patients with DM1 and the HCs coincided with distinct UVol 
responses. Data are presented as mean with SEM and were 
tested with a paired t- test. *P<0.05 MAP/UVol HSD versus 
LSD; #p<0.05 UNa HSD vs LSD. DM1, type 1 diabetes; HC, 
healthy control; HSD, high- salt diet; LSD, low- salt diet; MAP, 
mean arterial pressure; UNa, urinary sodium; UVol, urinary 
volume.
pro- B- type natriuretic peptide (NT- proBNP), and plasma 
volume but not in stroke volume or ECFV (table 1). In 
these patients, there was no correlation between changes 
in BP and changes in either CO, HR, plasma volume, 
ECFV, or NT- proBNP (figure 2). In healthy controls, HSD 
induced significant increases in body weight but not in 
BP, CO, HR, NT- proBNP, plasma volume, stroke volume 
or ECFV (table 1). There was an inverse correlation 
between HSD- induced changes in BP and HSD- induced 
changes in CO in this group (figure 2). PRA and aldo-
sterone showed a significant decrease after HSD in both 
groups (p<0.05). HSD did not change the aldosterone/
PRA in both groups. Also, changes in PRA and aldoste-
rone were not correlated to changes in BP or plasma 
volume.
ConClusIons
In the present study, we demonstrate that young, normo-
albuminuric and normotensive male patients with type 
1 diabetes show a salt- sensitive BP response to HSD, 
which is absent in matched healthy controls. Although 
both groups showed a mean increase in plasma volume, 
CO, NT- proBNP, and HR, responses were more homoge-
neous and, accordingly, only statistically significant in the 
patient group with type 1 diabetes, despite the smaller 
group size. Stroke volume as well as the aldosterone:PRA 
ratio did not change in response to HSD in both groups.
Despite the mean±2 L HSD- induced ECFV increases 
in our study, these increases did not reach statistical 
significance. Although this may be the result of a power 
problem, the change appeared to be similar in both 
groups and therefore does not seem to have caused the 
differential BP response. This is in line with the absence of 
a correlation between ECFV and BP changes. The ±2.5 kg 
increase in body weight after HSD in both groups may 
reflect the ECFV increase, yet contributions of increases 
in intracellular fluid volume or body fat mass29 cannot 
be excluded with certainty. It may be noted that a recent 
study did not find any difference in ECFV after 1- week 
dietary salt loading in healthy individuals, in which the 
difference between LSD and HSD approximated 8 g (vs 
±18 g in our study).30 The similarity in ECFV in patients 
with type 1 diabetes and healthy controls on LSD and 
HSD is consistent with previous studies in normoalbu-
minuric patients with type 1 diabetes, since only in the 
presence of advanced chronic kidney disease ECFV was 
increased.11 31
The mechanisms underlying the observed plasma 
volume response in patients with type 1 diabetes need 
further exploration. It may reflect increased sodium 
retention caused by (exogenously administered) insulin, 
given its sodium- retaining effects.32 The extent of 
volume retention in response to salt is also interlinked 
with the extent to which individuals are able to store 
sodium without concurrent water retention in certain 
compartments of their body.33 Titze et al has shown that 
a significant amount of sodium can be stored in tissues 
like the skin, in concentrations that far exceed plasma 
levels.34 High interstitial sodium content is known to be 
present in a variety of salt- sensitive conditions like type 
2 diabetes,35 chronic kidney disease,36 and hyperten-
sion,37 and may preclude further sodium buffering in 
response to a salt overload. Whether there is an effect of 
exogenous insulin on sodium storage is yet unknown but 
may be worth exploring.32 It remains to be determined 
whether in patients with type 1 diabetes reduced sodium 
storage capacity in response to salt loading underlies 
their response in plasma volume. Volume retention was 
also shown to be associated with vasodysfunction in salt- 
sensitive healthy individuals.38 Laffer et al showed that 
salt- resistant individuals show a decrease in systemic 
vascular resistance after salt loading by mechanisms not 
yet completely elucidated but possibly involving nitric 
oxide- related effects or neural pathways.38 39 In the 
present study, a significant decrease in systemic vascular 
resistance could, however, not be demonstrated, possibly 
due to the heterogeneity in BP responses in healthy 
controls (ie, seven out of 12 healthy controls showing a BP 
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Figure 2 Correlation analyses between MAP and volume- dependent and hemodynamic parameters. (A) There was no 
correlation between changes (HSD–LSD) in ECFV and MAP (patients with type 1 diabetes: r=0.19, p=0.66; healthy controls: 
r=−0.31, p=0.33). (B) There was no correlation between changes (HSD–LSD) in plasma volume and MAP (patients with type 
1 diabetes: r=0.38, p=0.36; healthy controls: r=−0.54, p=0.08). (C) There was a correlation between changes (HSD–LSD) in 
CO and MAP in healthy controls (r=−0.92, p<0.01) but not in patients with type 1 diabetes (r=0.47, p=0.24). (D) There was 
no correlation between changes (HSD–LSD) in HR and MAP (patients with type 1 diabetes: r=0.24, p=0.57; healthy controls: 
r=−0.51, p=0.11). (E) There was no correlation between changes (HSD–LSD) in NT- proBNP and MAP (patients with type 1 
diabetes: r=0.17, p=0.70; healthy controls: r=0.08, p=0.80). CO, cardiac output; ECFV, extracellular fluid volume; HR, heart rate; 
HSD, high- salt diet; LSD, low- salt diet; MAP, mean arterial pressure; NT- proBNP, N- terminal pro- B- type natriuretic peptide; PV, 
plasma volume.
increase and five showing a decrease) (table 1). However, 
the trend towards a decrease in systemic vascular resis-
tance in healthy controls and the absence of a decrease 
in patients with type 1 diabetes might point to vasodys-
function in the latter, which would be in accordance with 
recent concepts, proposing that vasodysfunction rather 
than impaired renal sodium excretion is the key causal 
factor in a salt- sensitive BP rise.14 38 The nature of the 
increase in NT- proBNP may lie in pressure overload as 
well as volume expansion, although we could not demon-
strate a correlation between changes in NT- proBNP and 
BP, systemic vascular resistance, or plasma volume in the 
present study (data not shown).
The HSD- induced increase in HR in our study is 
surprising and in contrast with a recent meta- analysis 
of 63 randomized controlled trials that showed a 2.4% 
increase in HR with salt reduction rather than with salt 
loading.40 Reasons for this remain to be established, but 
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may involve differences in measurement methods or 
conditions (in our case, non- invasive continuous hemo-
dynamic monitoring after at least 15 min of supine 
rest), study population, or the nature of the salt inter-
vention. The higher plasma osmolality in type I diabetes 
may have caused the HR increase, as it has been shown 
that plasma osmolality rises increase sympathetic nerve 
activity.41 42
Finally, HSD increased 24- hour urine volume in 
patients with type 1 diabetes but not in healthy controls. 
As the increased diuresis was not accompanied by 
differences in changes of solute- free water clearance, 
solute- mediated water clearance, or electrolyte- free 
water clearance compared with healthy controls, differ-
ences may be caused by differences in fluid intake. In 
both groups, HSD resulted in an increase in free water 
retention as evidenced by the negative solute- and 
electrolyte- free water clearance, likely reflecting osmot-
ically stimulated vasopressin release.
With regard to the excessive cardiovascular risk 
of patients with type 1 diabetes, which is importantly 
mediated by hypertension development,43 our data 
bear clinical importance. It underlines the importance 
of avoidance of excessive salt intake, as recommended 
in this patient group.43 Also, the observed increased 
sensitivity to salt may contribute to the increased 
cardiovascular risk of these patients even independent 
of BP, since it has been shown that individuals who are 
normotensive on the longer term but have been previ-
ously tested as salt sensitive show increased mortality, 
although by mechanisms still unknown.44 It should be 
noted that the extent of salt reduction needs further 
research. Paradoxically, a 1- week LSD has been demon-
strated to induce relative hyperfiltration in the kidney 
in patients with type 1 diabetes.8 Also, cohort studies 
showed increased mortality with highest but also with 
lowest salt intake in patients with type 1 diabetes45 and 
in patiens with type 2 diabetes,46 although possibly 
hampered by inaccurate estimations of salt intake and 
confounding.47 48
The major strength of our study is that—to our 
knowledge—we are the first to measure body fluid 
composition in conjunction with BP after salt loading 
in patients with type 1 diabetes using validated and 
precise PK methods, instead of relying on estimations 
based on body weight or bioimpedance methods that 
can be troubled by several factors.49 Furthermore, we 
included a well- matched control group and subjected 
study participants to a randomized dietary protocol 
that adheres to recent recommendations.18 However, 
certain study limitations need to be considered. The 
small sample size generates the possibility of a type II 
error. Notwithstanding possible effects on BP, volume 
and hemodynamic responses in healthy controls that 
could have been observed with a larger sample size, 
effect sizes in patients with type 1 diabetes were more 
pronounced and homogeneous, suggesting a more 
pronounced salt- sensitive phenotype. It should be 
noted that this study is not established to provide 
causal assessment between the observed BP increase 
and responses in body fluid composition and hemo-
dynamics, among others, since there were no sequen-
tial measurements before and during BP responses. 
For example, it has been shown that increases in 
plasma volume33 50 or CO do not automatically lead 
to BP increases (reviewed in Kurtz et al14). Our study 
serves as a hypothesis- generating study that precisely 
characterized responses to dietary salt loading in 
patients with type 1 diabetes. For underlying mecha-
nisms, future studies specifically aimed at this question 
should be performed. Also, since only male subjects 
were included, future studies are needed to explore 
whether our results can be extrapolated to females. 
Lastly, we did not control fluid intake; therefore, 
underlying reasons for the observed differences in 
urine volume cannot be identified with certainty.
In conclusion, we demonstrated that young normo-
tensive normoalbuminuric male patients with type 1 
diabetes are more sensitive to the effects of salt intake 
on BP than healthy individuals. The salt- sensitive BP 
rise in patients with type 1 diabetes was accompanied 
by significant increases in plasma volume, CO, HR, 
and NT- proBNP. Future studies are needed the scru-
tinize underlying mechanisms—like sodium storage 
capacity—in order to be able to ultimately unravel the 
susceptibility to hypertension and cardiovascular risk in 
patients with diabetes.
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